In continuation of its earlier intimations dated 13th February, 2026 and 06th March, 2026, wherein the Stock Exchanges were informed that Alkem Medtech, a wholly owned subsidiary of the Company in India (‘Alkem Medtech’), intends to acquire at least 51% and up to 55% of the total issued equity share capital of Occlutech Holding AG(‘Occlutech’), a company incorporated in Switzerland and had executed Share Purchase Agreement with the selling shareholders of Occlutech respectively. In this regard, Alkem Laboratories has informed that on 26th June, 2026, Alkem Medtech has executed First Supplementary Agreement to Share Purchase Agreement dated 6th March, 2026 with the selling shareholders of Occlutech. A copy of this disclosure will be made available on the Company’s website in accordance with Regulation 30(8) of the SEBI LODR Regulations.
The above information is a part of company’s filings submitted to BSE.
